Seelaus Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Seelaus Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-14,300	Closed	-$51K	–	167
2019 Q1	$51K	Hold	14,300	–	–	0.05%	158
2018 Q4	$55K	Hold	14,300	–	–	0.06%	137
2018 Q3	$135K	Hold	14,300	–	–	0.11%	165
2018 Q2	$104K	Hold	14,300	–	–	0.09%	164
2018 Q1	$71K	Buy	14,300 +1,500	+12%	+$7.94K	0.06%	173
2017 Q4	$65K	Buy	+12,800	New	+$75K	0.06%	175

Other funds holding ABUS

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Seelaus Asset Management's ABUS Position: Q2 2019 in Review

Seelaus Asset Management sold out of Arbutus Biopharma (ABUS) in Q2 2019, closing a stake of 14,300 shares — an estimated $51K sold.

Seelaus Asset Management first reported a position in ABUS in Q4 2017 and held it in 6 quarters. The position peaked at $135K in Q3 2018. 62 funds tracked by Wall St. Rank hold ABUS as of Q2 2019.

Seelaus Asset Management reported no remaining Arbutus Biopharma position as of Q2 2019 after selling out during the quarter.
Seelaus Asset Management sold 14,300 Arbutus Biopharma shares in Q2 2019, an estimated $51K.
Seelaus Asset Management first reported a position in Arbutus Biopharma in Q4 2017 and held it in 6 quarters.
Seelaus Asset Management's Arbutus Biopharma position peaked at $135K in Q3 2018.
62 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2019.

Based on Seelaus Asset Management's 13F filing for Q2 2019, filed 31 Jul 2019.